- Home
- GNLX vs SLS Comparison
GNLX vs SLS Comparison
Compare GNLX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | SLS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 208.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | SLS |
|---|---|---|
| Price | $2.92 | $4.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $19.75 | $7.00 |
| AVG Volume (30 Days) | 355.3K | ★ 14.3M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.85 |
| 52 Week High | $8.54 | $5.18 |
Technical Indicators
Market Signals| Indicator | GNLX | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 65.21 |
| Support Level | $2.52 | $3.69 |
| Resistance Level | $2.80 | $4.42 |
| Average True Range (ATR) | 0.34 | 0.60 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 16.17 | 64.99 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.